This story discusses suicide. If you or someone you know is having thoughts of suicide, please contact the Suicide & Crisis Lifeline at 988 or 1-800-273-TALK (8255).

Bunnie XO, the wife of country singer Jelly Roll, is discussing how a weight-loss medication may have led to her experiencing a “dark” depression.

During an episode of her podcast “Dumb Blonde,” Bunnie, whose real name is Alyssa DeFord, revealed that she had been taking a new drug by Lilly called retatrutide (reta), which is currently in late-stage trials and not approved by the FDA.

WHAT ARE GLP-3S? MEET THE NEW GENERATION OF WEIGHT-LOSS DRUGS WITH THREE KEY INGREDIENTS

Bunnie, 45, confirmed that she received her dose from a “reputable wellness center” in Nashville, and felt sick within the first week. Within two weeks, she noticed she looked and felt slimmer. In the fourth week, she increased her dose by one unit, which is when she noticed the “mental numbness.”

“I literally got sent into the worst suicidal depression that I’ve had since 2020,” she said. “I’m talking like it scared me so bad. I didn’t think I was going to make it through the two weeks. Like I was praying to God.”

The podcaster shared how she had “no emotion” and couldn’t listen to music that would typically “bring me joy.”

“You could see like my eyes were black,” she said. “I just drove in silence because I just couldn’t handle anything. It was either overstimulating or it was to the point where it just stole my joy. I had no joy, like nothing to live for. It was so dark.”

OBESITY EXPERT REVEALS THE BEST WAY TO DECIDE IF GLP-1S ARE RIGHT FOR YOU

After 20 days off the drug, Bunnie reported that her joy is “finally” returning, calling the experience a “battle.”

“My story is not what’s going to happen to you,” she shared with her listeners. “There’s so many people who are taking reta and love it and all that. But something happened with me.”

Indiana-based drug-maker Lilly confirmed in a statement to Fox News Digital that retatrutide is an “investigational molecule that is legally available only to participants in Lilly’s clinical trials.”

“No one should consider taking anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial,” the spokesperson wrote. “This was not a Lilly product, and the company continues to warn the public about the potential dangers of fake medicines.”

“This was not a Lilly product and the company continues to warn the public about the potential dangers of fake medicines.”

Fox News senior medical analyst Dr. Marc Siegel reacted in an interview with Fox News Digital, warning that retatrutide should not be taken while it has still not received FDA approval unless it is part of a clinical trial.

“This drug is new — known as a triple agonist (GLP-1, GIP and glucagon receptor agonist),” he said. “[It] has been linked potentially to depression and suicidal thoughts, as have the GLP-1 drugs, where some studies have shown increased psychiatric risks, so there is a potential link here.”

What is retatrutide?

The drug has received the nickname “GLP-3” because it targets the three hormones, which experts suggest could lead to more substantial weight loss.

Lilly announced results from its phase 3 trial TRIUMPH-4 in December, which tested retatrutide’s effect on weight loss and other health conditions.

Participants with obesity and knee arthritis who took a 12-mg dose of retatrutide saw an average weight loss of 71.8 lbs (28.7%) at 68 weeks.

“We believe retatrutide could become an important option for patients with significant weight loss needs and certain complications, including knee osteoarthritis,” a Lilly spokesperson said in a statement to Fox News Digital.

Seven additional phase 3 trials for retatrutide are expected to wrap up in 2026. The drug could see FDA approval in 2027, according to GoodRx.

STUDY REVEALS HOW RAPIDLY WEIGHT COMES BACK AFTER QUITTING OBESITY MEDICATIONS

Despite limited data availability on the drug, the medication could also be applied to treat other conditions like type 2 diabetes, kidney disease, cardiovascular risk reduction and metabolic dysfunction, according to GoodRx and other experts.

Siegel confirmed that retatrutide’s side effects can be similar to other GLP-1s, including gastrointestinal symptoms and other rare reactions like pancreatitis, gallstones and heart arrhythmia.

Philip Rabito, M.D., a specialist in endocrinology, weight loss and wellness in New York City, shared in a previous interview with Fox News Digital that this new class of weight-loss drugs is positioned to “approach bariatric surgery level outcomes” — although it doesn’t come without risks.

“The novel glucagon‑agonist component introduces less‑understood long‑term safety considerations, so it is imperative that patients are followed closely by healthcare professionals experienced with this class of medicines, with cautious, stepwise use, despite the impressive efficacy,” he cautioned.

The mental health connection 

The potential link between mental health symptoms and weight-loss drugs is most likely due to the impact on the brain’s reward system, according to Siegel.

“Dopamine, serotonin and norepinephrine affect mood and appetite, reduce cravings and can have a positive effect on mood, but also can be negative,” he said. “Somewhat unpredictable.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Dr. Peter Balazs, a hormone and weight-loss specialist in New York and New Jersey, noted that any presentation of significant depressive symptoms, particularly those including “psychotic features and suicidal ideation,” requires a full clinical evaluation.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“It is essential to understand the patient’s complete medical and psychiatric history, including other medical conditions, precise weight change dynamics, concomitant medications and psychosocial stressors,” he said. “Major depressive episodes are multifactorial — attributing them to a single agent without this context is premature.” 

Any individual experiencing these symptoms should “seek immediate professional help,” Balazs said.

“We are still learning about the psychiatric effects of these medications, even the ones that have already been approved,” he added.

CLICK HERE FOR MORE HEALTH STORIES

Bunnie’s age would typically place her in the perimenopausal stage, which can include “significant fluctuations” in reproductive hormones like estrogen, Balazs noted.

“Estrogen has well-documented neuroprotective and mood-stabilizing effects,” he said. “Its decline can render the brain more vulnerable to stress and dysregulation, potentially precipitating or exacerbating depressive episodes.”

Obesity can also cause hormone shifts and inflammation that can interfere with normal brain function, sometimes affecting mood and emotional balance, the expert noted.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Balazs stressed that experts should be “vigilant” in monitoring symptoms of people taking these medications. 

“Until a protocol is established, patients outside clinical trials should not inject these medications,” he cautioned. “Dose and dose-related responses can change the whole experience.”

Use left and right arrow keys to navigate between menu items.

Use escape to exit the menu.

The Department of Health and Human Services (HHS) is launching a study on whether radiation from cellphones could harm Americans’ health.

“The FDA removed web pages with old conclusions about cellphone radiation while HHS undertakes a study on electromagnetic radiation and health research to identify gaps in knowledge, including on new technologies, to ensure safety and efficacy,” HHS spokesperson Andrew Nixon said in a statement to Fox News Digital.

The study is part of a strategy report released last year by President Donald Trump’s MAHA Commission, Nixon added.

FOOD PYRAMID FACES SCRUTINY AS BEN CARSON REVEALS WHY AMERICANS DON’T HAVE TO EAT MEAT

The report urges officials to address electromagnetic radiation (EMR) exposure stemming from the widespread use of cellphones, Wi-Fi routers, cell towers and wearable, such as smartwatches.

In 2018, the National Institutes of Health did a study concluding there is “clear evidence” that high exposure to radio frequency radiation (RFR) was associated with cancer in male rats.

“In our studies, rats and mice received RFR across their whole bodies. By contrast, people are mostly exposed in specific local tissues close to where they hold the phone,” said senior scientist John Bucher at the time.

Bucher added, “The exposure levels and durations in our studies were greater than what people experience.”

The study did not investigate the RFR that is used for Wi-Fi or 5G networks.

HHS Secretary Robert F. Kennedy Jr. told USA TODAY on Friday that “electromagnetic radiation is a major health concern,” adding that he is “very concerned about it.”

A spokesperson for CTIA, the mobile carrier industry trade group, told Fox News Digital there is no credible evidence linking wireless devices to health problems.

“Radiofrequency energy from Wi-Fi and Bluetooth devices, mobile phones and wireless infrastructure has not been shown to cause health problems, according to the consensus of the international scientific community and independent expert organizations around the world,” said the spokesperson.

The World Health Organization has noted on its website that research shows “no adverse health effect has been causally linked with exposure to wireless technologies.”

CLICK HERE FOR MORE LIFESTYLE STORIES

In the U.S., cellphones must comply with Federal Communications Commission (FCC) limits on radiofrequency (RF) exposure.

The FCC uses a metric called specific absorption rate (SAR), which tracks how much RF energy the body absorbs. To be sold in the U.S., mobile phones and similar wireless devices must be tested and certified to ensure that they do not exceed 1.6 W/kg (watts per kilogram), averaging over 1 gram of tissue.

The FCC states on its website that there is “no scientific evidence currently establishing a definitive link between wireless device use and cancer or other illnesses.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

However, the agency does share ways that Americans can reduce exposure — such as shortening the amount of time spent on wireless devices, putting a phone on speaker or using an earpiece “to reduce proximity to the head and thus head exposure.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The FCC also recommends increasing the distance between wireless devices and the body, and texting instead of talking when possible.

Fox News Digital reached out to HHS and NIH for additional comment, as well as several major cellphone carriers.